Condition (MeSH)
Anetoderma
ClinicalTrials.gov lists 8 trials for Anetoderma or a narrower condition beneath it. Gyroscope Therapeutics Limited has the most among industry and government lead sponsors, with 5.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
8 of the 8 trials are tagged with Anetoderma itself; the rest are tagged with a narrower condition beneath it.
When did Anetoderma trials start? (7)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1/2
- Phase 2
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2023 | 1 |
| 2022 | 1 |
| 2020 | 1 |
| 2019 | 2 |
| 2018 | 1 |
| 2017 | 1 |
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Anetoderma trials in? (3)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 2 |
| Phase 2 | 4 |
| Observational | 2 |
How many Anetoderma trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Enrolling by invitation | 1 |
| Active, not recruiting | 2 |
| Completed | 1 |
| Terminated | 4 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Anetoderma trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Gyroscope Therapeutics Limited | 5 |
| Complement Therapeutics | 1 |
| Kubota Vision Inc. | 1 |
Which serious adverse events do Anetoderma trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Cerebrovascular accident | 12 | 3 |
| Atrial fibrillation | 10 | 2 |
| Fall | 10 | 3 |
| Hip fracture | 8 | 2 |
| Pneumonia | 8 | 3 |
Showing 5 of 10 adverse events.
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Primary anetoderma | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Primary anetoderma | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Primary anetoderma | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Primary anetoderma | 228272 | Exact | Orphadata Science knowledge files, Product 1 |
| Primary anetoderma | 228272 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: publications and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.